Bo Ma , Sheng Zheng , Ning Xie , Juan Yang , Xueli Zeng , Pei Liu , Shunling Zhang , Ji Li
{"title":"Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway","authors":"Bo Ma , Sheng Zheng , Ning Xie , Juan Yang , Xueli Zeng , Pei Liu , Shunling Zhang , Ji Li","doi":"10.1016/j.ejbt.2025.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Metformin (MET) is a dietary polyphenolic compound that exhibits anti-inflammatory and antioxidant properties. This study evaluated the protective effects of MET in both <em>in vitro</em> and <em>in vivo</em> models against potassium bromate (KBrO<sub>3</sub>)-induced hepatotoxicity. Hepatic cells were exposed to KBrO<sub>3</sub> with or without metformin (20, 40, and 60 µM), and cell viability and Reactive Oxygen Species levels were assessed. <em>In vivo,</em> rats were divided into five groups: control, KBrO<sub>3</sub>, and KBrO<sub>3</sub> with metformin (25, 50, and 100 mg/kg). Liver and blood samples were analyzed for histological changes, oxidative stress markers, lipid peroxidation, liver enzymes, and PI3K/Akt signaling.</div></div><div><h3>Results</h3><div>KBrO<sub>3</sub> exposure significantly decreased cell viability and increased ROS levels. Co-treatment with MET dose-dependently restored cell viability, with 60 µM MET achieving approximately 80% viability. Metformin also reduced ROS levels, with mean fluorescence intensity approaching control values at higher concentrations. In the <em>in vivo</em> study, KBrO<sub>3</sub> exposure elevated lipid peroxidation markers, depleted antioxidant enzyme activities, and triggered oxidative stress and inflammation. Metformin significantly alleviated histological liver damage, suppressed proinflammatory cytokines, enhanced antioxidant enzyme activities, and modulated the PI3K/Akt signaling pathway to promote cell survival and reduce oxidative injury.</div></div><div><h3>Conclusions</h3><div>Metformin effectively protects hepatic cells against KBrO<sub>3</sub>-induced cytotoxicity by improving cell viability and reducing Reactive Oxygen Species levels. Metformin successfully mitigates KBrO<sub>3</sub>-induced hepatic injury by reducing oxidative stress, modulating inflammatory pathways (NF-kB), and regulating the PI3K/Akt signaling cascade, offering molecular evidence of its hepatoprotective effects.</div><div><strong>How to cite:</strong> Ma B, Zheng S, Xie N, et al. Metformin mitigates potassium bromate induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway. Electron J Biotechnol 2025;76. <span><span>https://doi.org/10.1016/j.ejbt.2025.03.002</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":11529,"journal":{"name":"Electronic Journal of Biotechnology","volume":"76 ","pages":"Pages 1-11"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0717345825000144","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Metformin (MET) is a dietary polyphenolic compound that exhibits anti-inflammatory and antioxidant properties. This study evaluated the protective effects of MET in both in vitro and in vivo models against potassium bromate (KBrO3)-induced hepatotoxicity. Hepatic cells were exposed to KBrO3 with or without metformin (20, 40, and 60 µM), and cell viability and Reactive Oxygen Species levels were assessed. In vivo, rats were divided into five groups: control, KBrO3, and KBrO3 with metformin (25, 50, and 100 mg/kg). Liver and blood samples were analyzed for histological changes, oxidative stress markers, lipid peroxidation, liver enzymes, and PI3K/Akt signaling.
Results
KBrO3 exposure significantly decreased cell viability and increased ROS levels. Co-treatment with MET dose-dependently restored cell viability, with 60 µM MET achieving approximately 80% viability. Metformin also reduced ROS levels, with mean fluorescence intensity approaching control values at higher concentrations. In the in vivo study, KBrO3 exposure elevated lipid peroxidation markers, depleted antioxidant enzyme activities, and triggered oxidative stress and inflammation. Metformin significantly alleviated histological liver damage, suppressed proinflammatory cytokines, enhanced antioxidant enzyme activities, and modulated the PI3K/Akt signaling pathway to promote cell survival and reduce oxidative injury.
Conclusions
Metformin effectively protects hepatic cells against KBrO3-induced cytotoxicity by improving cell viability and reducing Reactive Oxygen Species levels. Metformin successfully mitigates KBrO3-induced hepatic injury by reducing oxidative stress, modulating inflammatory pathways (NF-kB), and regulating the PI3K/Akt signaling cascade, offering molecular evidence of its hepatoprotective effects.
How to cite: Ma B, Zheng S, Xie N, et al. Metformin mitigates potassium bromate induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway. Electron J Biotechnol 2025;76. https://doi.org/10.1016/j.ejbt.2025.03.002.
期刊介绍:
Electronic Journal of Biotechnology is an international scientific electronic journal, which publishes papers from all areas related to Biotechnology. It covers from molecular biology and the chemistry of biological processes to aquatic and earth environmental aspects, computational applications, policy and ethical issues directly related to Biotechnology.
The journal provides an effective way to publish research and review articles and short communications, video material, animation sequences and 3D are also accepted to support and enhance articles. The articles will be examined by a scientific committee and anonymous evaluators and published every two months in HTML and PDF formats (January 15th , March 15th, May 15th, July 15th, September 15th, November 15th).
The following areas are covered in the Journal:
• Animal Biotechnology
• Biofilms
• Bioinformatics
• Biomedicine
• Biopolicies of International Cooperation
• Biosafety
• Biotechnology Industry
• Biotechnology of Human Disorders
• Chemical Engineering
• Environmental Biotechnology
• Food Biotechnology
• Marine Biotechnology
• Microbial Biotechnology
• Molecular Biology and Genetics
•Nanobiotechnology
• Omics
• Plant Biotechnology
• Process Biotechnology
• Process Chemistry and Technology
• Tissue Engineering